MD Anderson's David M. Gershenson, MD, Receives IGCS's Award for Excellence in Gynecologic Oncology
For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society's (IGCS) Award of Excellence. Gershenson, professor and past chair of the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, received the award at the IGCS's 15th Biennial Meeting in Melbourne, Australia. William J. Hoskins, MD., of Memorial Sloan Kettering, also was honored with the distinction.The IGCS is a not-for-profit, independent organization contributing to the prevention, treatment and study of gynecologic cancer, as well as improvement in the quality of life among women suffering from such diseases throughout the world.In recognizing Dr. Gershenson, the organization notes him as an exemplar in forwarding the scientific knowledge of gynecological cancers, and, more specifically, of the non-epithelial ovarian cancers."Dr. Gershenson's role in the diagnosis and clinical management of these tumors has been of the top level globally. Many around the world, who are also accomplished and knowledgeable in this area, consult him about issues related to the care of women with these tumors," says the IGCS in a press release. "Through his generosity, countless patients beyond MD Anderson have benefited from his wisdom and unique breadth of experience."Gersh...
Authors: Higashihara T, Okada A, Nakamura Y, Saigusa H, Homma S, Matsumura M, Kusano T, Shimizu A, Takano H Abstract We performed a renal biopsy for nephrotic syndrome in a patient with squamous cell lung carcinoma, which can worsen the prognosis. Chemoradiation therapy was effective for the cancer and proteinuria; we thus inferred that the nephrotic syndrome had been closely associated with the carcinoma. A pathological analysis of the kidney showed monoclonality for λ chain, satisfying the diagnostic criteria of proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID); however, con...
ConclusionsThe results of this study showed that lung volume changes were not a cause for concern in breast cancer patients. There are three reasons to support this conclusion. Lung volume changes and percentage reductions in LVP for each Gy increase of MLD and each percentage increase of V20 in each lobe were small; patients were asymptomatic during the follow-up period; and LVP showed partial improvements after 6 months.
ConclusionUsing robust optimization for skin flash in breast IMRT planning is feasible. Further investigation is warranted to confirm the clinical effectiveness of this novel approach.
AbstractThe use of conventional chemotherapy in the treatment of cancer has been restricted by the lack of cell specificity, which causes toxicity regarding healthy cells resulting in limiting side effects responsible for low therapeutic efficiency. To overcome these drawbacks, the design of prodrugs has evolved and improved by covalently linking the drug through a degradable spacer. The use of these prodrugs as drug delivery systems, which are able to inactivate the drug during its biodistribution to specifically deliver the drug to its target, is an important breakthrough in cancer therapy. This strategy consisting in th...
ConclusionsThe exposure –response analysis suggested that intermittent 7-day veliparib 120 mg BID dosing in a 21-day cycle provided additional efficacy without meaningfully impacting the safety and tolerability when co-administered with carboplatin and paclitaxel in patients with BRCA-deficient breast cancer. A higher d ose of veliparib is unlikely to provide greater benefit in this combination in patients with BRCA-deficient recurrent or metastatic breast cancer.
AbstractThioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key members of the Trx system that is involved in redox regulation and antioxidant defense. In recent years, several researchers have provided information about the roles of the Trx system in cancer development and progression. These reports indicated that many tumor cells express high levels of Trx and TrxR, which can be responsible for drug resistance in tumorigenesis. Inhibition of the Trx system may thus contribute to cancer therapy and improving chemotherapeutic agents. There are now a number of effective natural and synthetic inhibitors with chemo...
Date: Wednesday, 10 16, 2019; Speaker: Rowan Chlebowski, MD, PhD, Chief and Senior Investigator, Harbor-UCLA Medical Center; Building: Building 10 (Clinical Center); Lipsett Amphitheater
Date: Thursday, 11 14, 2019; Speaker: Ulrike Lorenz, Ph.D., Associate Professor, Dept. of Microbiology, Immunology, and Cancer Biology, University of Virginia; Building: Building 6B; 4B-429
The prostate cancer community mourns the loss of Gerald Chodak, MD, an influential and iconic figure in urology.Medscape Urology
Conclusions: Our findings suggest that adenine inhibits the growth of colon cancer cells. Anticancer activity of adenine in colon cancer cells is attributable to the activation of apoptotic signaling and in turn the AMPK/mTOR pathway. Adenine represents a natural compound with anticancer potency. PMID: 31611925 [PubMed]
More News: Biology | Cancer | Cancer & Oncology | Carcinoma | Clear Cell Carcinoma | Clinical Trials | Education | Epithelial Cancer | Funding | Genetics | Germ Cell Tumors | Grants | Health | Men | Molecular Biology | Mucinous Carcinoma | Mucinous Ovarian Cancer | OBGYN | Ovarian Cancer | Ovaries | Serous Carcinoma | Study | Teaching | Texas University | Universities & Medical Training | Women